Amicus Therapeutics, INC 8-K filings

Amicus Therapeutics, Inc. has been acquired by BioMarin Pharmaceutical Inc. through a merger, with shareholders receiving $14.50 per share in cash.

Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted clearance for its merger with BioMarin Pharmaceutical Inc., satisfying a key condition for the transaction's closure.

Amicus Therapeutics stockholders overwhelmingly approved the company's acquisition by BioMarin Pharmaceutical Inc. at a special meeting held on March 3, 2026.

Amicus Therapeutics disclosed preliminary unaudited 2025 financial results, including $634 million in total net product revenues, amidst its proposed acquisition by BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, totaling approximately $4.8 billion.

Amicus Therapeutics reported strong third-quarter 2025 financial results, achieving GAAP net income of $17 million on total revenues of $169 million, up 17% at constant exchange rates.

Amicus Therapeutics announced robust second-quarter 2025 financial results, driven by strong sales of Galafold and Pombiliti + Opfolda, and reaffirmed its full-year financial guidance, including GAAP profitability in H2 2025.

Amicus Therapeutics, Inc. announced the successful election of its Class III directors and the approval of its 2025 Equity Incentive Plan, auditor ratification, and executive compensation on an advisory basis at its Annual Meeting of Stockholders held on June 5, 2025.

Amicus Therapeutics secures exclusive U.S. rights to Dimerix's DMX-200, a Phase 3 drug candidate for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease.

Amicus Therapeutics reports a 15% year-over-year revenue increase in Q1 2025 and expands its portfolio by in-licensing DMX-200 for rare kidney disease.

Amicus Therapeutics files an opinion of Troutman Pepper Locke LLP regarding the legality of its common stock shares in connection with registering remaining unsold shares under its existing at-the-market program.

Amicus Therapeutics reports a 33% increase in total revenue for 2024, reaching $528.3 million, and projects continued growth and profitability in 2025.

Amicus Therapeutics reports strong 2024 revenue growth of 32% and provides a positive strategic outlook for 2025, driven by Galafold and Pombiliti + Opfolda.

Amicus Therapeutics reported a strong third quarter in 2024, with a 37% year-over-year revenue increase, leading to raised full-year revenue growth guidance and reduced operating expense projections.

Amicus Therapeutics has reached a settlement with Teva Pharmaceuticals, granting them a license to market a generic version of Galafold in the U.S. starting in 2037.

Amicus Therapeutics announced a 34% year-over-year increase in total revenue for Q2 2024, driven by strong sales of Galafold and Pombiliti + Opfolda, leading to an increase in full-year revenue guidance and achieving non-GAAP profitability.

Amicus Therapeutics held its 2024 Annual Meeting of Stockholders on June 6, 2024, electing three Class II directors and approving several key proposals.

Amicus Therapeutics announced a 28% year-over-year increase in total revenue for the first quarter of 2024, driven by strong sales of Galafold and the successful launch of Pombiliti + Opfolda, leading to raised full-year revenue guidance.

Amicus Therapeutics announced a 21% increase in total revenue for 2023, reaching $399.4 million, and anticipates full-year non-GAAP profitability in 2024.